| Paroxysmal nocturnal hemoglobinuria
Bkemv vs Fabhalta
Side-by-side clinical, coverage, and cost comparison for paroxysmal nocturnal hemoglobinuria.Deep comparison between: Bkemv vs Fabhalta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsFabhalta has a higher rate of injection site reactions vs Bkemv based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Fabhalta but not Bkemv, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Bkemv
Fabhalta
At A Glance
IV infusion
Every 2 weeks
Complement C5 inhibitor
Oral
Twice daily
Factor B inhibitor
Indications
- Paroxysmal nocturnal hemoglobinuria
- Atypical Hemolytic Uremic Syndrome
- Myasthenia Gravis, Generalized
- Paroxysmal nocturnal hemoglobinuria
- IGA Glomerulonephritis
- Complement 3 Glomerulopathies
Dosing
Paroxysmal nocturnal hemoglobinuria 600 mg IV weekly for 4 weeks, then 900 mg at week 5, then 900 mg every 2 weeks thereafter.
Atypical Hemolytic Uremic Syndrome, Myasthenia Gravis, Generalized 900 mg IV weekly for 4 weeks, then 1,200 mg at week 5, then 1,200 mg every 2 weeks thereafter.
Atypical Hemolytic Uremic Syndrome (pediatric, <18 years) Weight-based IV dosing: induction 300-900 mg and maintenance 300-1,200 mg every 2-3 weeks depending on body weight (5 kg and over).
Paroxysmal nocturnal hemoglobinuria, IGA Glomerulonephritis, Complement 3 Glomerulopathies 200 mg orally twice daily without regard to food; swallow capsules whole.
PNH Patients Switching From Anti-C5 Initiate FABHALTA no later than 1 week after last eculizumab dose or no later than 6 weeks after last ravulizumab dose.
Contraindications
- Unresolved serious Neisseria meningitidis infection
- Serious hypersensitivity to iptacopan or any of the excipients
- Unresolved serious infection caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria meningitidis, or Haemophilus influenzae type b (contraindicated for initiation)
Adverse Reactions
Most common (>=5%) Headache, nasopharyngitis, back pain, nausea, fatigue, cough, herpes simplex infections, musculoskeletal pain, hypertension, diarrhea, vomiting, pyrexia, peripheral edema.
Serious Meningococcal infections, other serious infections, thrombosis, infusion-related reactions, disease manifestation exacerbation after discontinuation.
Postmarketing Fatal or serious infections (Neisseria gonorrhoeae, Neisseria meningitidis, Neisseria species), cholestatic or mixed pattern liver injury with elevated liver enzymes and bilirubin.
Most common (>=10%) headache, nasopharyngitis, diarrhea, abdominal pain, bacterial infection, viral infection, nausea, rash
Serious serious infections caused by encapsulated bacteria, hyperlipidemia
Pharmacology
Complement C5 inhibitor; eculizumab-aeeb is a recombinant humanized monoclonal IgG2/4kappa antibody that specifically binds complement protein C5 with high affinity, inhibiting its cleavage to C5a and C5b and preventing generation of the terminal complement complex C5b-9, thereby inhibiting terminal complement-mediated intravascular hemolysis in PNH and complement-mediated thrombotic microangiopathy in aHUS.
Factor B inhibitor; iptacopan binds to Factor B of the alternative complement pathway, regulating C3 cleavage and inhibiting downstream effectors to control both C3b-mediated extravascular hemolysis and terminal complement-mediated intravascular hemolysis in PNH, and to inhibit complement-driven glomerular injury in IgAN and C3G.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Bkemv
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
Fabhalta
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Bkemv
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Fabhalta
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (5/8)
Humana
Bkemv
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (0/3)
Fabhalta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Bkemv.
Cost estimate not availableAssistance Fund: Immunoglobulin A Nephropathy (IgAN)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
FabhaltaView full Fabhalta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.